FDA May Modify Orphan Exclusivity Reg, But Label Carve-Out Policy Is Intact

A district court rejects FDA’s “clinical superiority” requirement for Gralise orphan exclusivity, while another court upholds the agency’s finding that an ANDA label carve-out may overlap partially with a protected method of use.